MindImmune Therapeutics engineers therapies that target the immune system’s role in neurodegeneration, aiming to curb the neuroinflammatory processes that accelerate diseases like Alzheimer’s. Its research identifies and modulates specific biological pathways responsible for inflammation-driven neuronal damage. The company is advancing a new class of drug candidates designed to meaningfully change the course of neurodegenerative disorders rather than merely treating symptoms. With its latest capital, MindImmune plans to complete critical translational studies and prepare an Investigational New Drug (IND) submission to the FDA. The funding will also underwrite strategic planning for the program’s first clinical trials, bringing its lead candidates closer to human testing. Although revenue figures have not been disclosed, the $5 million infusion strengthens the firm’s financial runway as it moves from preclinical work toward early clinical development.

Total raised

$15M

Funding rounds

3

Latest round

Equity

Latest activity

Mar 2026